In addition to his role at Mission Bay Capital, Barry Selick is Vice Chancellor for Business Development, Innovation and Partnerships at the University of California, San Francisco (UCSF). Prior to joining UCSF, he was the CEO of Threshold Pharmaceuticals, a NASDAQ-listed biotech company which he led from its initial venture capital financing in 2002 until March 2017. He was also a Venture Partner at Sofinnova Ventures from June 2002 until July 2007. Prior to Threshold, Barry co-founded and was CEO of Camitro, a venture-backed biotech company located in Menlo Park, CA, as well as founded and was Chairman of Camitro UK, Ltd., located in Cambridge, UK. Both companies were acquired by ArQule 2 years after founding. Before Camitro, Barry was at Affymax Research Institute, which was acquired by Glaxo Wellcome, plc as its drug discovery technology development center and where Barry was Vice President of Research, responsible for technology development and drug discovery. Prior to Affymax, Barry was a Staff Scientist and Senior Scientist, respectively, at Protein Design Labs (PDL) and Anergen. While at PDL, he, along with Cary Queen, invented the technology for humanizing mouse monoclonal antibodies as therapeutics and applied that to daclizumab, the first FDA-approved fully humanized antibody therapeutic, that was licensed to and commercialized by Roche for the prevention of kidney transplant rejection. Approximately 16 different therapeutics benefitting patients with a variety of cancers, as well as inflammatory, respiratory, and autoimmune diseases have subsequently been developed based on this technology.
With a BA in Biophysics and PhD in Biology from the University of Pennsylvania, Barry was a Damon Runyan-Walter Winchell Cancer Fund Fellow as well as a Senior Fellow of the American Cancer Society at UCSF. He has sat on and/or chaired a number of Boards of Directors of both private and public biotech companies.